MYGN · Myriad Genetics Inc
United States · RS rating 89 · As of 2026-11-03
| Price | 6.04 USD |
|---|---|
| 1-day change | +3.2% |
| RS rating (overall / 1M / 3M / 12M) | 89 / 97 / 97 / 34 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 39 / 35 / 50 |
| Industry group (rank) | Medical-Research Eqp/Svc (46) |
| EPS growth Q/Q | +72.4% |
| Sales growth Q/Q | +2.0% |
| Distance from 52-week high | +26.2% |
| Market cap (USD) | $452.4M |